

Automation of AroCell's TK 210 ELISA in China

AroCell today announced the signing of an additional agreement with ZECEN Biotech for the development of the company's third tumor marker product, TK 210 ELISA, which will be included on ZECEN Biotech's automated platforms. This partnership marks a major milestone for AroCell as we continue to expand our product offerings and improve cancer diagnostics.

AroCell has been collaborating with ZECEN Biotech since 2019 for the development of TPS CLIA on ZECEN Biotech and Fosun's automated CLIA platforms, which are now available on the Chinese market. There is also an ongoing collaboration for the automatization of UBC that started earlier this year. The addition of a third marker, TK1, to automated platforms is consistent with AroCell's strategy to make its biomarkers available to a larger patient population and further strengthen AroCell's presence in the Chinese market.

"The company's strategy is to include our tumor markers on automated platforms. We are very happy to start another development project with ZECEN Biotech to include the tumor marker TK1 on their fully automated CLIA system," says Paola Pellegrini, Product Manager at AroCell.

"We believe that including TK1 on ZECEN Biotech's automated platforms will help us achieve our goal of improving cancer diagnostics," says Anders Hultman, CEO of AroCell. He added, *"Automating tumor markers reduces the risk of human error and increases the efficiency of the diagnostic process, enabling healthcare professionals to diagnose cancer faster and more accurately. Introducing TK1 on automated platforms in China is a major step forward for AroCell."*

About ZECEN Biotech

ZECEN Biotech Co., Ltd., is a Chinese company that mainly specializes in providing complete solutions for chemiluminescence immunoassay by developing, manufacturing, and marketing CLIA instruments and reagents. The company has research and development centers and a production base in Beijing, Shandong, and Jiangsu. ZECEN Biotech Co., Ltd., and cooperates with leading hospitals in China.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About Thymidine Kinase 1

Thymidine Kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is up-regulated during the S phase of the cell cycle and degraded in mitosis. Its presence in cells indicates active cell proliferation. Increased levels of TK1 in the blood can indicate abnormal cell turnover or disruption of cells in active proliferation triggered by, for example, therapeutic agents.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-17 10:30 CEST.

Attachments

[Automation of AroCell's TK 210 ELISA in China](#)